Incretin‐based antiobesity medications (AOMs), including GLP‐1 and GLP‐1/GIP receptor agonists, have transformed obesity management by delivering substantial and sustained weight loss alongside metabolic benefits [13, 14, 15]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.